Joel Neal, MD, PhD
Publication Details
-
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Nat Rev Clin Oncol. 2010; (2): 71-2
Nat Rev Clin Oncol. 2010; (2): 71-2
Help
Trial Administration